Introduction
Cancer is a progressive disease that is often fatal even though removal and treatment of the primary tumor is often successful. The most insidious feature of cancer is its spread to and compromise of distant organs via the complex process of metastasis. It is now well established that cancer development usually follows a course of progression through increasingly aggressive and treatment-resistant stages that re¯ect the accumulation of molecular genetic changes. While tumor initiation re¯ects unscheduled cellular hyperproliferation, either through direct activation of cell cycle machinery or of signaling pathways that directly regulate the cell cycle, progression to malignancy and metastasis re¯ects changes in the intimate relationship between a tumor cell and its host environment. For this reason, the mouse as a model organism provides the most physiologically relevant setting in which to study and molecularly dissect the process of metastasis in vivo.
Metastasis is often thought of in terms of the hurdles that tumor cells must overcome in order to successfully metastasize (reviewed in Ruoslahti, 1999) . Thus, tumor cells must invade their surrounding extracellular milieu; for epithelially-derived carcinomas this may include degradation and passage through a collagen-IV-rich basement membrane, while mesenchymally-derived sarcomas invade the loose fibrillar collagen matrix of connective tissue. The concomitant invasion of neovasculature into the tumor, solicited by the tumor cells themselves, facilitates the juxtaposition of tumor cell and blood vessel. Metastasizing cells must then cross the slightly dierent basement membrane surrounding a blood vessel and invade between the vascular endothelial cells into the circulation in a process known as intravasation. Here they must survive in the circulation in a state of suspension (no small feat for epithelial cells, which normally undergo apoptosis when deprived of adhesion in a process known as anoikis (Schwartz, 1997) ). Colonization involves lodging in a distant capillary bed, extravasation back out of the blood vessel and subsequent survival, invasion and proliferation in what is now a foreign microenvironment for those cells. The process of extravasation is thought to model many aspects of normal lymphocyte tracking; the study of lymphocyte:endothelial cell interactions has provided important clues toward understanding tumor cell behavior (reviewed in Buck, 1995) . The events subsequent to entering the circulation are thought to be rate-limiting; of the large number of tumor cells that successfully enter the circulation, only a small percentage can actually successfully colonize a distant organ such as the liver or lung (StetlerStevenson et al., 1993) . Some studies even suggest that most tumor cells successfully extravasate, but fail to subsequently colonize the target organ (Koop et al., 1995; Yu et al., 1997) , suggesting that survival and proliferation in a foreign milieu is a particularly challenging hurdle to tumor cells.
The process of tumor angiogenesis or neovascularization clearly plays a critical role in tumor development and metastasis, and is an essential component of tumor-host interactions, however, such a discussion is beyond the scope of this review and the reader is referred to several excellent recent reviews (Fidler and Ellis, 1994; Twardowski and Gradishar, 1997; Zetter, 1998) . Instead, the molecular events that have been implicated in tumor cell invasion and dissemination will be reviewed, with particular emphasis on the past and future use of mouse models to study and dissect the metastatic process.
Genetic changes associated with metastasis
Given such a complex set of processes, it is not surprising that the de®nition of genetic changes underlying the acquisition of those behaviors has been dicult. It is dicult to`catch' tumor cells in the act of breaking individual barriers, particularly during late stages of tumorigenesis when tumor heterogeneity and genomic instability is mounting. Moreover, the increasingly realized contribution of non-cell autonomous factors, such as from surrounding normal stromal cells, to tumor progression, suggests that a genetic analysis of the tumor cells themselves may miss important contributing factors. Finally, unlike the process of tumorigenesis itself, animal models of metastatic progression are uncommon, rendering the study of the process in a tractable and physiologically relevant system dicult.
Historically, there have been numerous well-established correlations between the expression of certain tumor markers and advanced disease or poor patient prognosis, suggesting a functional relationship between the marker and tumor progression (reviewed in Sherbet and Lakshmi, 1997) . In addition, the de®nition of genomic intervals that exhibit frequent loss or ampli®cation during tumor progression implicates the function of contained genes in tumor progression. While several good candidates have been identi®ed in this way (examples include nm23, KAI1, kiSS-1 (Dong et al., 1995; Lee et al., 1996; Steeg et al., 1988) functional con®rmation for a role in metastatic progression has not yet been forthcoming.
Experimental models of metastasis
Attempts to experimentally model metastasis begin with rudimentary in vitro assays designed to recapitulate individual facets of the metastatic process such as cell motility and invasion. There are a number of ways to measure cell motility, and several forms of motility to measure. For example, random motility or haptotaxis can be measured by videomicroscopy, while directed motility can be measured by scraping a monolayer of cells in culture and monitoring their ability to migrate back into the`wounded' area (Nobes and Hall, 1999) .
In vivo, motility becomes a three dimensional process; cellular invasion is often measured using a device called a Boyden or transwell chamber which constitutes a barrier in culture through which cellular invasion can be monitored and quantitated. Cells crawl through a ®lter riddled with 8 mm pores; the ®lter can be covered with reconstituted ECM such as Matrigel which mimics a collagen IV-rich basement membrane, ®bronectin, laminin, or a ®brillar collagen I-like meshwork (for example, see Qian et al., 1999) . Similarly, an investigation of the ability of cells to enter and traverse thick (*2 mm) collagen gels or a monolayer of extracellular matrix-producing stromal cells has been used to recapitulate cellular invasion. In each case, chemotactic invasion can be measured by ®lling the low chamber with a source of growth factor.
The complex nature of metastasis dictates the need for experimental systems that more closely mimic endogenous contributing factors. One extensively used assay takes advantage of the relative ease of access to the developing chick embryo via a window in the egg shell. The chorioallantoic membrane (CAM) of the chick is a blood vessel-rich and accessible membrane onto which tumor cell xenografts can be placed and their ability to intravasate into nearby blood vessels and disseminate can be studied in vivo in a live embryo (reviewed in Quigley and Armstrong, 1998) . In order to assay human tumor cell intravasation using this model, Kim et al. (1998) employed the clever trick of quantitating disseminated Alu repetitive sequences by PCR; Alu repetitive elements are abundant throughout the human genome and absent from that of the chick.
In the mouse, several experimental assays are utilized to model metastatic spread in vivo; there are advantages and disadvantages to each. Each assay involves the injection of tumor cells at speci®c anatomical locations and analysis of their ability to form tumors and/or to colonize distant sites via hematogenous spread. The classic assay attempts to model the later stages in successful metastasis; cells are injected directly into the tail vein of syngeneic or immunocompromised mice and their ability to form colonies in the lung is evaluated. Labeling the input cells with a vital dye or through GFP transgene expression allows them to be tracked by the process of intravital microscopy (Chishima et al., 1997; Koop et al., 1996) . This assay fails to measure the earlier invasive and angiogenic stages of malignant progression, and therefore may be an incomplete measure of metastatic capability. However, even less rigorous is the injection of tumor cells directly into the peritoneum and evaluation of their ability to`seed' the surrounding mesothelium. This assay at best measures the ability of tumor cells to adhere and survive under those conditions. Finally, perhaps a truly more physiological assay involves subcutaneous (or occasionally, foot pad) injection of tumor cells and evaluation of their ability to form tumors and spontaneously invade, enter the circulation and successfully metastasize.
Endogenously arising metastasis in the mouse is a surprisingly infrequent event compared to that associated with human cancer; it has long been postulated that an understanding of the reason for this discrepency will reveal important insight into the molecular basis of metastasis. However, for this reason, true models of endogenously arising metastasis in the mouse have not been well-studied. The use of transgenic and knockout technology has presented a couple of notable exceptions to this rule (i.e. Guy et al., 1992; McClatchey et al., 1998) ; the study of these animals and expanded use of genetic manipulation of the mouse genome will undoubtedly have a tremendous impact on our ability to model and study metastasis in vivo in the mouse.
Cellular behaviors associated with metastasis: adhesion, motility and invasion
By studying the cellular activities acquired by metastatic cells, researchers have established links between proteins that normally carry out such functions and metastatic behavior. Prominent among these are proteins involved in cell adhesion, motility and invasion. For example, the altered function of both cell : cell and cell : ECM adhesion molecules has been implicated in virtually all stages of metastatic progression.
Loss or loosening of cellular adhesion is often correlated with early stages of tumor progression as cells break away from the primary tumor (Ruoslahti, 1999) . For example, loss of the cell : cell adhesion molecule E-cadherin is associated with the invasive behavior of carcinomas and is thought to facilitate an epithelial-to-mesenchymal transition reminiscent of the naturally occurring developmental phenomenon. Epithelial cells, which are largely nonmotile, often utilize E-cadherin to establish tight cell : cell adhesion in an epithelial monolayer. During several developmental contexts, loss of cadherin expression is associated with a programmed epithelial-to-mesenchyme transition and the organized migration of an epithelial cell population such as neural crest cells; upon reaching their destinations, neural crest cells reexpress (N)-cadherin (Nakagawa and Takeichi, 1998) .
In a transgenic model of pancreatic b-cell carcinoma (Rip1Tag2 mice), loss of E-cadherin is unequivocally associated with the transition from adenoma to carcinoma (Hanahan and Folkman, 1996) . Importantly, combined transgenic overexpression of wildtype E-cadherin prevented adenoma to carcinoma transition in this model, while a dominant negative E-cadherin dramatically increased the frequency of adenoma to carcinoma transition and led to the appearance of lymph node metastases, which were never seen in the parental model (Perl et al., 1998).
Interestingly, germline mutations in E-cadherin have been recently identi®ed in association with a particularly invasive form of familial gastric cancer (Guilford et al., 1998) . Although the invasive nature of the tumors that develop in these patients supports the idea that E-cadherin loss of function contributes to tumor invasiveness, the fact that the mutations are predisposing raises the possibility that E-cadherin loss also plays a role in tumor initiation.
While cadherins are the best known class of cell : cell adhesion molecules expressed on epithelial cells, integrins are the major known class of cell:ECM molecules expressed on a wide variety of cell types (reviewed in Schwartz, 1997) ; similarly, alterations in the expression and function of integrins, during the transition to invasive and metastatic behavior are welldocumented (see Sherbet and Lakshmi, 1997) . Altered integrin function may facilitate tumor progression and metastatic spread in several ways. First, the increased invasiveness and acquisition of motile behavior exhibited by tumor cells may be driven by increased or promiscuous integrin-mediated adhesion. Furthermore, whereas normal cells undergo either integrindependent growth arrest (®broblasts) or anoikis (epithelial cells) upon detachment from extracellular matrix, tumor cells gain anchorage independence (Keely et al., 1998; Schwartz, 1997) . This process is likely to be important in both the invasive stage of tumor metastasis, during hematogenous or lymphoid transit to a distant site and at the point of metastatic colonization. Importantly, recent studies indicate that while oncogenes such as src and ras can bypass both serum-and anchorage-dependence, overexpression of the oncogenes focal adhesion kinase (FAK), Bcr-Abl or the small GTPase Rho, speci®cally bypasses anchorage-dependence, demonstrating the importance of disabling this pathway for cell transformation (Schwartz, 1997) . Finally, beyond their function in cell adhesion, integrins may aect tumor development and progression through the activation of integrindependent signaling cascades and/or through the control of extracellular matrix deposition and assemblage (Ruoslahti, 1999) .
Human tumors often exhibit organ-speci®c patterns of metastasis that cannot be completely explained by the proximity of certain capillary beds. Some evidence suggests the existence of an address system whereby tumor cells preferentially recognize and adhere to organ-speci®c vasculature or stroma. This idea is supported by studies that have identi®ed the existence of organ-speci®c vascular cell-surface markers (Pasqualini and Ruoslahti, 1996; Rajotte et al., 1998) . In fact, the redirection of tumor cell metastasis to the bone has been achieved in vivo in mice through the forced expression of a4b1 integrin on the surface of tumor cells (Matsuura et al., 1996) . Tumor neovasculature has also been shown to elaborate unique cell-surface markers; the targeting of therapeutic drugs to tumor neovasculature in the mouse is currently under investigation as a novel therapeutic strategy .
Attempts to block integrin function in experimental models of metastasis in vivo using blocking antibodies or peptides have been somewhat successful (Ruoslahti, 1999) , however, initial attempts to examine the eects of diminished integrin or integrin substrate (fibronectin; FN) function using knockout mice have not revealed an important role for these proteins in tumorigenesis or metastasis (Taverna et al., 1998) . These studies were restricted by the early lethality of both a5 integrin and FN null embryos, necessitating the use of heterozygous mutant animals; the advent of conditional gene targeting in the mouse will provide an exciting avenue through which to evaluate the importance of individual integrin function in speci®c tumor and metastasis models in vivo.
Invasiveness also involves the expression and/or activation of ECM-degrading proteases, which can be organized into four classes: serine proteases, aspartyl proteases, cysteine proteases and the largest class, matrix metalloproteases (MMPs) (reviewed in Westermarck and Kahari, 1999) . Altered expression of each of these enzymes has been linked to tumor progression in some context. ECM protease function plays an important role in early tumor invasion, neovascularization and in metastatic colonization; whether proteases are produced in an autocrine fashion by tumor cells or via paracrine stimulation of surrounding stromal cells is an unresolved, yet important issue. Interestingly, it has recently been demonstrated that the integrin avb3 can bind to and present the matrix metalloprotease MMP-2 on the surface of invasive tumor cells, suggesting an additional mechanism by which integrins can participate in tumor metastasis (Brooks et al., 1996) . Similarly, the hyaluronic acid receptor CD44, which has repeatedly been implicated in tumor mestastasis, has recently been shown to bind to and present the matix metalloprotease MMP-9 on its surface (Yu and Stamenkovic, 1999) ; whereas it has long been assumed that the hyaluronic acid binding function of CD44 is responsible for its link to tumor metastasis, these observations may suggest an alternative mechanism. Importantly, it is not clear in either case whether the tumor or the surrounding host stroma would provide a source of MMP-2 or MMP-9.
The role of ECM proteases in tumor progression is now being investigated using transgenic technology to remove or overexpress speci®c proteases or their inhibitors and examine the resulting eect upon tumor development and progression. For example, host de®ciency for the plasminogen activator inhibitor (PAI1), paradoxically prevented tumor invasion and angiogenesis of malignant keratinocyte but not melanoma tumor cell xenografts (Bajou et al., 1998) . This could re¯ect a requirement for the serine protease plasminogen during the neovascularization process. Interestingly, crossing of APC min heterozygous mutant mice, which develop numerous intestinal polyps modeling familial adenomatous polyposis, to mice homozygous for a null mutation in the metalloprotease matrilysin resulted in a signi®cant decrease in polyp number and size without an increase in invasive behavior (Wilson et al., 1997) . While this study does not rule out a critical role for MMP function in intestinal tumor progression, it does imply an unexpected role for matrix metalloproteases in tumor initiation, suggesting that these molecules may play dual roles in both tumorigenesis and metastasis (reviewed in Chambers and Matrisian, 1997) . Similarly, transgenic overexpression of collagenase in the mouse epidermis increased tumor susceptibility in a two-stage carcinogenesis protocol without aecting tumor invasion (D'Armiento et al., 1995) .
One molecular signaling network is repeatedly implicated in metastasis
As increasing connections and correlations between the function and/or expression of individual molecules and the process of tumor metastasis are made, so are increasing links within and between molecular signaling pathways established, such that one particular signaling network emerges as being repeatedly implicated in metastastic progression. This network involves signaling via the Rho family of small GTPases that control cytoskeletal reorganization. The three prototypic Rho GTPases, RhoA, Rac1 and Cdc42, are best known for their classic eects on the actin cytoskeleton; thus activation of RhoA, Rac1 and Cdc42 aect the formation of stress ®bers, membrane rues and ®lopodia, respectively (Hall, 1998) . It is now well recognized that the Rho GTPases do more than reorganize the cytoskeleton; they also control cellular activities such as adhesion, motility and proliferation, probably through the regulation of several well-studied signaling pathways including the integrins themselves. Rho GTPases control integrin function by controling their localization through reorganization of the actin cytoskeleton. In addition, Rho GTPases regulate the stress-activated kinases c-jun-N-terminal kinase (JNK) and p38, as well as the serum response factor (SRF) (reviewed in Ip and Davis, 1988; Keely et al., 1998; Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998) . Both of these pathways act on components of the AP-1 transcription factors; thus JNK phosphorylates and activates c-jun while SRF binds to and activates transcription of c-fos via the serum response element (SRE) found in its promoter. Homodimeric or heterodimeric complexes of jun or jun/fos family members comprise the AP-1 transcriptional activity in a cell. AP-1, in turn, regulates the activity of a number of target genes (Karin et al., 1997) .
Roles for the Rho GTPases in cell transformation and tumorigenesis have emerged from several directions and primarily establish a link between Rho GTPase function and Ras-mediated transformation (Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998) . The identi®cation of the p190 RhoGAP protein and demonstration that it also interacts with p120 RasGAP, a negative regulator of Ras, suggested a mechanism by which the two pathways converged (Settleman et al., 1992) . Moreover, multiple lines of evidence suggest that Rho GTPase function is required for ecient Ras-induced transformation (reviewed in Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998) . The Rho GTPases are members of the Ras superfamily of small GTP binding proteins that cycle between active, GTP-bound and inactive, GDP-bound states. As for Ras proteins, speci®c guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) function as positive and negative regulators of the Rho GTPases. In fact, several known Rho family GEFs were originally identi®ed as oncogenes that could directly cause transformation of NIH3T3 cells (i.e. Dbl, ost; Van Aelst and D'SouzaSchorey, 1997).
The Rho GTPases have also been ®rmly associated with cell motility and invasion (Keely et al., 1998) . The coordinated action of all three Rho family members and Ras itself have been proposed to drive cell motility in scrape wound assays in vitro (Nobes and Hall, 1999) . Thus it has been suggested that Cdc42 functions to establish ®broblast polarity in preparation for movement, Rac propels movement itself through lamellipodial exploration, Rho drives the adhesion necessary to crawl through the formation of integrin-containing focal adhesions and Ras promotes localized focal adhesion turnover in order to generate traction. In fact, Rho GTPase function has been linked to that of the hepatocyte growth factor/scatter factor (HGF/SF), which promotes the motility and invasion of epithelial cells and has been linked to metastatic progression (Ridley et al., 1995) . Rho GTPases are also required for the three-dimensional invasion of epithelial cells in collagen gels, perhaps through the activity of phosphatidylinositol-3-OH kinase (PI(3)K) (Keely et al., 1997) . One of the major known eector kinases activated by RhoA, p160 ROK can promote invasion of hepatoma cells through a mesothelial monolayer (Itoh et al., 1999) . Finally, a screen designed to identify genes that enhance lymphocyte invasion through a ®broblast monolayer in vitro and in experimental metastasis assays in vivo led to the identi®cation of Tiam-1, a GEF for the Rho family member Rac1 (Habets et al., 1994) . Importantly, introduction of Tiam-1 into noninvasive cells was found to confer invasive behavior.
It has recently been determined that important targets of Rho GTPase signaling are the ERM family of cytoskeleton:membrane linker proteins. The ERM proteins are phosphorylated and relocalized to the membrane:cytoskeleton interface in response to Rho activation; in fact, p160 ROK can directly phosphorylate the ERM C-terminus (Matsui et al., 1998) . Interestingly, a dominant negative form of ezrin blocks HGF induced cell scattering, suggesting a positive role for ezrin in cell motility (Crepaldi et al., 1997) . In fact, ezrin has been reported to be a direct substrate of the HGF receptor, Met (Crepaldi et al., 1997) . A fourth, although somewhat divergent member of the ERM family is the Nf2 tumor suppressor, merlin. Mutations in the NF2 tumor suppressor gene underlie the familial cancer syndrome neuro®bromatosis type II (NF2), which features the development of benign nervous system tumors, particularly schwannomas (reviewed in Gusella et al., 1999) . Surprisingly, Nf2 heterozygous mutant mice develop malignant tumors (osteosarcomas, ®brosarcomas and hepatocellular carcinomas) that metastasize with a remarkably high frequency (McClatchey et al., 1998) . For example, nearly 100% of the Nf2-de®cient osteosarcomas (the tumors exhibit loss of the wild-type Nf2 allele) metastasize to the lung, liver and occasionally the kidney or spleen. Initial experimentation supports the notion that loss of Nf2 function contributes to metastatic progression in this model (McClatchey et al., 1998) . Importantly, the amino-terminus of all four proteins can interact with CD44, suggesting a possible mechanism by which loss of Nf2 leads to metastatic progression (Sainio et al., 1997; Tsukita et al., 1994) . Moreover, recent evidence suggests that merlin is regulated by and may regulate the activity of Rac and not Rho (Shaw RJ, Jacks T, AIM, unpublished results). Perhaps deregulation of Rac-controled signaling in the absence of Nf2 leads to increased metastatic potential. The elucidation of the molecular functions of this interesting family of proteins should provide important insight into the molecular basis of metastasis.
The eects of Rho GTPase signaling upon cell motility, invasion and metastasis may be achieved in part through the alterations in gene expression driven by the SRF and AP-1 transcription factors. For example, prominent among AP-1 regulated genes are the matrix metalloproteases and CD44 itself. Moreover, the use of gene targeting has revealed that c-fos is required for the malignant progression of skin tumors in vivo (Saez et al., 1995) . Finally, the fos family member fra-1, whose expression is controlled by AP-1, has been shown to confer invasiveness to epithelial cells in vitro (Kustikova et al., 1998) .
The future
The future of metastasis research lies in the generation and study of better mouse models. Primarily through the use of transgenic and gene targeting technology, an increasing repertoir of cancer prone mouse strains is now available; crosses between such cancer prone animals and strains of mice engineered to overexpress or fail to express metastasis related genes will be extremely informative. Alternatively, tail vein and/or subcutaneous injection of tumor cells into recipient hosts that misexpress various metastasis related genes will allow an investigation of tumor-host interactions.
Among powerful emerging technology is the ability to identify the genetic basis of phenotypic modi®cation in the mouse. With the nearing of the completion of a very high resolution map of the mouse genome and the acquisition of a set of polymorphic markers that represent high density saturation of the genome, the ability to map and clone such modifer loci becomes feasible (Marra et al., 1999; Rhodes et al., 1998) . As has been achieved in simpler organisms such as D. melanogaster, the undertaking of genetic modi®er screens in the mouse is now possible. The ®rst modi®er to have been identi®ed and cloned is the phospholipase A2 (PLAP2) locus which aects polyp number in the APC Min model (Dietrich et al., 1993; MacPhee et al., 1995) . Large scale screens to identify and ultimately clone modi®ers of a number of phenotypes is now underway in the mouse, including the search for genes that modify metastasis phenotype. This approach has been validated via the studies of Lifsted et al. (1998) who utilized a MMTV-polyoma middle T (MMTV-PyMT) model of metastatic mammary tumorigenesis to identify genetic loci that modify the metastatic phenotype. When this transgene was placed onto 27 dierent genetic backgrounds, large variations in tumor onset, size, and importantly, metastatic potential were seen. Similarly, investigation of genetic background dierences in the etiology of epidermal squamous cell carcinoma revealed that of those tested, only the FVB/n background supported progression from a dysplastic lesion to an invasive carcinoma (Coussens et al., 1996) .
Another emerging technology gaining widespread use is the utility of oligonucleotide chips or cDNA array technology to compare the total mRNA expression patterns of dierent cell populations (reviewed in Brown and Botstein, 1999) . This technology will undoubtedly be invaluable toward identifying genes involved in metastatic progression. For example, the expression pro®les of a metastasis vs parental primary tumor from the same animal can be compared.
Finally, the development of better models of endogenously arising metastasis in the mouse will facilitate the development and testing of rational treatments. Initially, the animal models themselves will provide valuable vehicles in which to test therapeutic strategies such as inhibitors of metalloprotease or integrin function. Ultimately the goal will be to utilize the information derived from the generation and study of these mouse models to treat metastasis in human cancer patients. It has often been asserted that treating a primary cancer is relatively easy; metastases are often untreatable and are the cause of most cancer deaths.
